This systematic review and meta-analysis tries to determine whether there is an association between the use of protease inhibitors (PIs) and the incidence of diabetes mellitus (DM) and/or metabolic syndrome (MS) in HIV-infected patients. A systematic literature search was performed using MEDLINE/PubMed, CENTRAL, LILACS, and EMBASE. Included articles were observational studies published on or prior to November 2015 that met specific inclusion criteria. Pooled relative risks (RRs) and hazard ratios (HRs) were calculated. Nine articles met the inclusion criteria, describing 13,742 HIV patients. Use of PIs was associated with the development of MS (RR: 2.11; 95% CI 1.28-3.48; p-value 0.003). No association between the use of PIs and development of DM was found: the HR for the incidence of DM among patients using PIs was 1.23 (95% CI 0.66-2.30; p-value: 0.51) and the RR was 1.25 (95% CI 0.99-1.58; p-value 0.06). Use of PIs in HIV-infected patients is associated with an increased risk of MS. No evidence of an increased risk of DM was found. However, because MS is a precursor to DM, it is possible that studies with a longer follow-up duration are needed in order to detect an association between PI use and onset of DM.
Introduction
Globally, 36.7 million people were living with HIV infection as of 2016. 1 Nearly two million new cases and one million deaths from HIV occur annually, and the number of deaths per year is decreasing due to the development and increased availability of new treatments. [1] [2] [3] [4] Currently, there are 19.5 million people living with HIV/AIDS (PLWHA) who receive highly active antiretroviral therapy (HAART), which is effective in prolonging the life expectancy of HIV-infected patients. 1, 5, 6 Because of these advances, there is an increased emphasis on not only decreasing mortality, but also on decreasing morbidity and improving quality of life among PLWHA. 1, 5, 6 HIV and HAART have been associated with various metabolic disorders, specifically Type 2 diabetes mellitus (DM). [7] [8] [9] [10] Another common metabolic disorder is the metabolic syndrome (MS), which is defined by the International Diabetes Foundation (IDF) as the clustering of the most significant risk factors for the development of myocardial infarction, and by the Adult Panel Treatment III as the presence of multiple risk factors for the development of cardiovascular disease. 11, 12 MS is also a risk factor for cardiovascular disease, cerebrovascular disease, and DM. 13 It is estimated that one quarter of the world's population has MS and the prevalence ranges from less than 10% up to 84% by country. 14 One of the principal disorders associated with HAART is elevated blood glucose, which is a component of MS 9,10 and a risk factor for DM. 7, 8 The Multicenter AIDS Cohort Study included 568 HIVinfected patients from which 411 were receiving HAART. In this study, the incidence of DM in the patients exposed to HAART was 14%; four times higher than among the nonexposed patients. 15 Another study found that the prevalence of MS among seropositive patients that received HAART was between 14 and 18%. 16 These risks do not, however, outweigh the benefits of HAART for the HIV patient. 17, 18 Protease inhibitors (PIs) are one of the most frequently prescribed class of antiretroviral drugs. 19 Several studies have reported associations between the use of PIs and the incidence of DM and MS. 9, 10, 20 PIs interact with adipose tissue, altering lipid metabolism by generating oxidative stress which modifies the secretion, differentiation, and autophagic activities of adipocytokines. 21, 22 Other PI mechanisms that contribute to the development of metabolic disturbances include the noncompetitive inhibition of GLUT-4 channels in adipose tissue and the decrease of insulin secretion, due to a signaling alteration and to the induction of apoptosis of beta pancreatic cells (Figure 1 ). Both disturbances would generate, in the long term, insulin resistance. [22] [23] [24] However, other studies have shown no significant association between the use of PIs and the development of any metabolic disorders. [25] [26] [27] In view of the conflicting literature related to the risk of metabolic disorders resulting from use of PIs, this systematic review and meta-analysis was performed to evaluate the association between the use of PIs and the development of DM and/or MS in HIV-infected adults (aged 18 years or older).
Methods
The systematic review protocol was registered at PROSPERO, an international database of systematic reviews (Registration number: CRD42015027223).
Data sources and searches
We searched for original studies that describe the association between the use of PIs and incidence of DM and/ or MS using MEDLINE/Pubmed, Cochrane Central Register of Controlled Trials -CENTRAL in The Cochrane Library, LILACS, and EMBASE. All studies published on or before November 2015 were considered. A gray literature search was also performed using Web of Science, the bibliography of relevant articles, abstracts of the International AIDS Society (IAS, 2001 (IAS, -2015 , 28 and the Conference on Retroviruses and Opportunistic Infections (CROI, 2014 (CROI, -2015 . 29 Finally, a manual search of journals known to publish relevant articles in this field was performed. Our search strategy based on the MeSH terms used for each database (PubMed, EMBASE, COCHRANE, LILACS) is further detailed in online Appendix 1. 
Study selection
We performed a literature search unrestricted by language or country of origin. We considered studies that involved the use of any PI since their availability until November 2015. We included prospective and retrospective cohort studies, case-control studies, and randomized clinical trials. The inclusion criteria were: (1) patients aged 18 years or older with HIV infection and treated with HAART, (2) patients compared according to their use of PIs, (3) DM and MS defined by the study, and (4) the presence of DM and/or MS described during follow-up.
Case reports, reviews, and cross-sectional studies were excluded due to the lack of follow-up. Likewise, we excluded studies that included patients with DM and/or MS at baseline. Lastly, we excluded studies with inadequate information about DM and/or MS, or where there was no information about PIs usage.
Data extraction and quality assessment
Two investigators independently checked titles, abstracts, and the full text of potentially relevant articles. Differences were resolved by a third investigator who decided if the study was included.
Data extraction was carried out individually by each investigator and discrepancies were resolved by consensus. For each study, detailed information including the year, country, type of study, measure of association, total number of participants, follow-up duration, and definitions of DM and MS was extracted.
In order to assess the methodological quality of each study, we used the Newcastle-Ottawa Scale (NOS), which assesses the selection process, comparability, and type of study. 30 
Data synthesis and analysis
We performed separate analyses for each of the outcomes. Heterogeneity of the estimated effects was assessed using the Cochrane Q test for heterogeneity and the I 2 statistic test. 31 A random-effects model was chosen due to the expected heterogeneity.
We analyzed the relative risk (RR) and hazard ratio (HR) of the selected studies, and, when possible, calculated the RR from the HR. All analyses were performed using the software program Review Manager 5.3.
Results
After eliminating duplicates, we identified and reviewed 4203 articles by titles and abstracts, of which 4086 were removed because they did not meet the inclusion criteria or were not relevant to the research topic ( Figure 2 ).
The full texts of the remaining 117 articles were reviewed, and 108 articles were excluded. We included nine articles for the quantitative analysis, six assessing the DM outcome, and three the MS outcome (Table 1 and 2). All of the included studies were cohort studies and all were written in English. The studies selected were from Asia (1), Europe (3), USA (5). The results of quality assessment for each study included in the systematic review using the NOS are described in online Appendix 2.
Incidence of MS
Within the three studies analyzed to determine the RR of developing MS after exposure to PIs, we found no evidence of an estimated effect heterogeneity in the analysis of the pooled RR (I 2 ¼ 0). An association between the use of PIs and developing MS was identified, with a pooled RR of 2.11 (CI 95%, 1.28-3.48; p-value 0.003) (Figure 3 ).
Incidence of DM
Within the three studies that evaluated the HR of developing DM after exposure to PIs, we found considerable estimated effect heterogeneity in the analysis of the pooled HR (I 2 ¼ 74%). The pooled HR for the association between the use of PIs and the appearance of DM was 1.23 (CI 95%, 0.66-2.30; p-value: 0.51) (Figure 4(a) ).
Upon evaluation of the four studies that evaluated the RR of developing DM after the exposure to PIs, we did not find a significant estimated effect heterogeneity in the analysis of the pooled RR (I 2 ¼ 15%). The pooled RR was 1.25 (CI 95%, 0.99-1.58; p-value: 0.06) (Figure 4(b) ).
Discussion
We found a 2.11 times greater risk of the development of MS among HIV-positive patients treated with a PIcontaining regimen than those treated with a PI-free HAART regimen. However, there was no association with the development of DM among patients treated with PIs. The heterogeneity between studies was low for studies evaluating MS and moderate to high in some of the studies evaluating DM.
The definition of MS was predicated based on the need to predict the risk of cardiovascular disease, cerebrovascular disease, and DM in clinical practice. 13 Although there are varying classifications for MS, the IDF criteria are suggested to be most strongly associated with the development of DM. 32 Generally, abdominal obesity precedes MS, and it has been shown that with aging and increased obesity further metabolic risk factors develop until the criteria for This study was divided according to the use of nelfinavir and indinavir. There was no multivariate analysis for the use of nelfinavir and the appearance of DM.
MS are reached, followed by an increased risk of the onset of DM. 33 So far, no study has evaluated the predictive value of MS in the appearance of DM among HIV-positive patients receiving antiretroviral treatment. 34 The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study group 35 has developed an instrument to predict the early risk of DM at two and five years since antiretroviral initiation. 36 In this study, the moderate, high, and very high risks of DM added up to 21 and 46% at two and five years of antiretroviral treatment, respectively. 36 A systematic review, that included studies based on the general population, found a close relationship between MS and the incidence of DM, particularly linked to increased waist circumference and impaired fasting glucose. 37 Increases in waist circumference are associated with increases in the quantity of adipose tissue, which in turn causes the functions associated with this tissue to be amplified. 38 One of these is the accelerated conversion of cortisone into cortisol, an insulin antagonist. 38 Simultaneously, increased adipose tissue results in decreased adiponectin production. Adiponectin plays an important role in insulin sensitivity and secretion. 38, 39 Furthermore, it has been shown that hyperglycemic periods increase insulin secretion, contributing to impaired fasting glucose. Thus, these factors, if sustained for a certain period, can lead to the development of insulin resistance and, subsequently, the development of DM. 40 One of the main limitations of the studies included in this analysis is the absence of an adequate follow-up time. Only four out of the nine studies we evaluated had a follow-up duration of four years or greater. MS is a condition that generally precedes DM, and the components of this syndrome have a comparatively early onset. 33 The studies designed to look for this outcome followed their patients up for approximately 1-3 years, enough time to find an association in the appearance of MS. On the other hand, DM is a late onset disease, and therefore requires a longer follow-up period in order to be detected. 41 It has been reported that it takes an average of 4-7 years, in some cases even decades, from the appearance of insulin resistance to the development of DM. 41 Furthermore, there is evidence that HIV-infected patients who receive HAART are at risk of premature morbidity and mortality compared to HIV-uninfected patients. 42 This is mainly because of residual immunodeficiency, chronic inflammation, and the toxicity of antiretroviral drugs. 42 For these reasons, studies that evaluate the incidence of DM require longer follow-up times.
Other identified limitations of the studies reviewed were their population sizes, inadequate information about the initiation of PIs, the absence of other reported risk factors for the studied outcomes, the division of the population into subgroups depending on received treatments, and the analysis of PIs as a group rather than each PI drug individually. The complete HAART regimen of each study population was not reported, because other antiretroviral drugs such as nucleoside reverse transcriptase inhibitors and nonnucleoside reverse transcriptase inhibitors are also related to metabolic abnormalities, especially those associated with lipid metabolism. Future studies should not only consider pharmacological families but also specific drugs due to their different associations with these alterations. 43, 44 A lack of control of potential confounders was another limitation found in the included studies. For instance, the study by Capeau et al. 53 did not perform a multivariate analysis of the use of nelfinavir and the development of DM, and the study by Palacios et al. performed a univariate analysis of the use of PIs and the appearance of MS. In both instances, the available data were incorporated into the analysis for our study. Because both MS and DM are multifactorial, adjustments to the analysis to account for potential unmeasured confounders such as time in receipt of HAART, family history of DM, and others that may affect the association between PI use and the appearance of MS and/or DM should be made. The main confounders recognized in different studies are gender, age, mode of HIV infection, ethnicity, CD4 cell count, viral load, smoking status, hypertension, weight, BMI, waist circumference, hepatitis B virus coinfection, hepatitis C virus coinfection, HAART naivety, and duration of previous HAART exposure. 45 Publication bias was not assessed using Egger's test nor by the visual inspection of asymmetry in the funnel plot, because the number of studies included was too small to have an acceptable power for the use of these tests. 46, 47 The use of PIs and the increased risk of myocardial infarction among PLWH are well known, therefore it is important to screen for dyslipidemia and the use of statins if there is risk for cardiovascular disease. 48 For this reason, screening for metabolic abnormalities must be considered at HIV diagnosis and as part of routine care. The possibility of adopting preventive measures, due to the increased risk of this morbidity in PLWH, should also be taken in consideration, especially in those receiving HAART.
There is evidence that older PIs have an increased association with insulin resistance, hyperglycemia, and diabetes compared to newer PIs. 48 In a small study, nine HIV-infected patients with PI-induced insulin resistance were switched to atazanavir, increasing their insulin sensitivity without compromising their viral load. 49 However, we consider that future studies should be performed with longer follow-up and including different populations with a larger sample size.
Conclusions
This study showed that the use of PIs in the treatment of HIV infection is associated with an increased risk of developing MS. However, we did not find an association between the use of PIs and the development of DM. These findings will be of relevance for public policy because it will increase the interest in screening and prevention of MS and DM in an expanding population. Future studies should have an adequate follow-up duration to account for the typically delayed onset of DM.
